The FDA has granted Fast Track designation to Biogen’s BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau for the treatment of Alzheimer disease (AD). In a press release ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback